Exact Mass: 560.2289
Exact Mass Matches: 560.2289
Found 251 metabolites which its exact mass value is equals to given mass value 560.2289
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Quizartinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Sotorasib
D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
Methyl (2R)-[(1S,2R,4S,5R,9R,10R,13R,14S,15S,17S)-17-acetoxy-9-(3-furyl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.02,4 04,13 05,10]octadec-15-yl](hydroxy)acetate
5alpha-acetoxy-20-(benzoyloxy)-2alpha,4alpha,7beta,9alpha,15-pentahydroxy-10-oxo-10,19-epoxy-11(15->1)abeo-tax-11(12)-ene|taiwantaxin B
4beta,15-dihydro-3beta-acetoxy-8beta-5(5-acetoxytigloyl)-4-hydroxytigloyloxyzaluzanin C|4beta,15-dihydro-3beta-acetoxy-8beta-5<5-acetoxytigloyl>-4-hydroxytigloyloxyzaluzanin C
20-acetoxy-2alpha-benxyloxy-4alpha,5alpha,7beta,9alpha,13alpha-pentahydroxy-11(15-1),11(10-9)bisabeotax-11-eno-10,15-lactone
(3R,3aR,5aS,6S,7aR,8S,9S,11S,13aS,14aR)-dodecahydro-3,8,9-trihydroxy-5,5,11-trimethyl-11-[(2S,3Z)-2-methyl-3-(4-methyl-5-oxofuran-2(5H)-ylidene)propanoyl]-2H,5H-6,8:9,13a-diepoxycycloocta[5,6]cyclohepta[1,2-c]furo[3,2-b]furan-2(14H)-one|schicagenin E
rel-(2R,3S,5S,1S,3R)-2,5,1,3-tetra(4-hydroxyphenyl)-4-methylene-4,5,3,4,6,7-hexahydro-1H,2H-spiro[furan-3,5-isobenzofuran]|ribesin H
1beta-O-beta-D-glucopyranosyl-15-O-(p-hydroxyphenylacetyl)-5alpha,6betaH-eudesma-3,11(13)-dien-12,6alpha-olide
1,3,6-Tri(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol
(rel-3R,3aS,4aR,5aS,7aS,8aR,11aR,13aS,15R,15aR,17S,17aS,17bS,17cS)-tetradecahydro-15,17-dihydroxy-3,4a,5a,13,13-pentamethyl-8H-7a,17-epoxy-10H-furo[3,2-b]furo[3,2:2,3]furo[3,4: 4,5]cyclohepta[1,2: 5,6]cycloocta[1,2:4,5]cyclopenta[1,2-d]furan-2,5,10,16-(3H,7H,13H)-tetrone|lancifodilactone R
3-O-beta-D-glucopyranosyl-14-O-(p-hydroxyphenylacetyl)-3beta,14-dihydroxycostunolide
His Glu Phe Glu
C29H36O11_7,11-Methano-2H,4H-oxireno[1,8]cycloocta[1,2-f][2]benzopyran-8-acetic acid, 10-(acetyloxy)-4-(3-furanyl)dodecahydro-alpha,11-dihydroxy-4a,7,9,9-tetramethyl-2,13-dioxo-, methyl ester, (alphaR,4R,4aR,7S,8S,10S,11S,11aR,12aS)
methyl (2R)-2-[(1S,2R,4S,9R,10R,14S,15S,17S)-17-(acetyloxy)-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-15-yl]-2-hydroxyacetate
methyl (2R)-2-[(1S,2R,4S,9R,10R,14S,15S,17S)-17-(acetyloxy)-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-15-yl]-2-hydroxyacetate_major
methyl (2R)-2-[(1S,2R,4S,9R,10R,14S,15S,17S)-17-(acetyloxy)-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,?.0?,¹³.0?,¹?]octadecan-15-yl]-2-hydroxyacetate
Cys Ile Tyr Tyr
Cys Leu Tyr Tyr
Cys Tyr Ile Tyr
Cys Tyr Leu Tyr
Cys Tyr Tyr Ile
Cys Tyr Tyr Leu
Glu Glu Phe His
Glu Glu His Phe
Glu Phe Glu His
Glu Phe His Glu
Glu His Glu Phe
Glu His Phe Glu
Phe Glu Glu His
Phe Glu His Glu
Phe His Glu Glu
Phe Met Thr Tyr
Phe Met Tyr Thr
Phe Thr Met Tyr
Phe Thr Tyr Met
Phe Tyr Met Thr
Phe Tyr Thr Met
His Glu Glu Phe
His Phe Glu Glu
His His His Met
His His Met His
His Met His His
His Asn Gln Tyr
His Asn Tyr Gln
His Gln Asn Tyr
His Gln Tyr Asn
His Tyr Asn Gln
His Tyr Gln Asn
Ile Cys Tyr Tyr
Ile Tyr Cys Tyr
Ile Tyr Tyr Cys
Leu Cys Tyr Tyr
Leu Tyr Cys Tyr
Leu Tyr Tyr Cys
Met Phe Thr Tyr
Met Phe Tyr Thr
Met His His His
Met Thr Phe Tyr
Met Thr Tyr Phe
Met Tyr Phe Thr
Met Tyr Thr Phe
Asn His Gln Tyr
Asn His Tyr Gln
Asn Asn Gln Trp
Asn Asn Trp Gln
Asn Gln His Tyr
Asn Gln Asn Trp
Asn Gln Trp Asn
Asn Gln Tyr His
Asn Trp Asn Gln
Asn Trp Gln Asn
Asn Tyr His Gln
Asn Tyr Gln His
Gln His Asn Tyr
Gln His Tyr Asn
Gln Asn His Tyr
Gln Asn Asn Trp
Gln Asn Trp Asn
Gln Asn Tyr His
Gln Trp Asn Asn
Gln Tyr His Asn
Gln Tyr Asn His
Thr Phe Met Tyr
Thr Phe Tyr Met
Thr Met Phe Tyr
Thr Met Tyr Phe
Thr Tyr Phe Met
Thr Tyr Met Phe
Trp Asn Asn Gln
Trp Asn Gln Asn
Trp Gln Asn Asn
Tyr Cys Ile Tyr
Tyr Cys Leu Tyr
Tyr Cys Tyr Ile
Tyr Cys Tyr Leu
Tyr Phe Met Thr
Tyr Phe Thr Met
Tyr His Asn Gln
Tyr His Gln Asn
Tyr Ile Cys Tyr
Tyr Ile Tyr Cys
Tyr Leu Cys Tyr
Tyr Leu Tyr Cys
Tyr Met Phe Thr
Tyr Met Thr Phe
Tyr Asn His Gln
Tyr Asn Gln His
Tyr Gln His Asn
Tyr Gln Asn His
Tyr Thr Phe Met
Tyr Thr Met Phe
Tyr Tyr Cys Ile
Tyr Tyr Cys Leu
Tyr Tyr Ile Cys
Tyr Tyr Leu Cys
9-[1,1-Biphenyl]-4-yl-9-phenyl-3,3-bi-9H-carbazole
9-[1,1-Biphenyl]-3-yl-9-phenyl-3,3-bi-9H-carbazole
[4-[(2-AMino-3-Methyl-1-oxobutyl)aMino]-2-hydroxy-5-phenyl-1-(phenylMethyl)pentyl]-carbaMic Acid 5-ThiazolylMethyl Ester Monohydrochloride
n-1,2,3,4-Tetrahydronaphth-1-yl-2-[3,5-dimethoxybenzamido]-2-deoxy-adenosine
Quizartinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
2-[(3R,6aR,8S,10aR)-1-(2-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-benzylpiperidin-1-yl)ethanone
2-[(3S,6aS,8R,10aS)-1-(2-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-[4-(phenylmethyl)-1-piperidinyl]ethanone
methyl (2R)-2-[(1S,2R,4S,5R,9R,10R,14S,15S,17S)-17-acetyloxy-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.02,4.04,13.05,10]octadecan-15-yl]-2-hydroxyacetate
Sotorasib
A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
K-Ras G12C-IN-4
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C[1].
(1r,2r,4s,6s,7r,8s,9r,10s,11r,13s,15s,16r,17r)-6,7,8,9-tetrahydroxy-8-(hydroxymethyl)-4,17-dimethyl-5-oxo-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-16-yl acetate
10,15,27-trihydroxy-9,15-dimethyl-7,12,20,25,28-pentaoxaheptacyclo[21.4.3.1⁸,¹¹.1¹⁰,¹⁴.0¹,²⁴.0⁹,¹⁸.0¹³,¹⁸]dotriaconta-4,22-diene-6,21,26-trione
(1s,3r,7r,10s,12r,13r,15s,16s,17s,18s,21r,22s,24r,26s)-12,15-dihydroxy-9,9,21,24,26-pentamethyl-4,8,19,23,29-pentaoxaoctacyclo[13.13.1.0¹,¹³.0³,⁷.0³,¹⁰.0¹⁶,²⁶.0¹⁷,²⁴.0¹⁸,²²]nonacosane-5,14,20,25-tetrone
methyl 2-[(1s,3s,5r,7s,8r,10s,12s,13r)-5-(acetyloxy)-13-[(5s)-5-hydroxy-2-oxo-5h-furan-3-yl]-6,6,8,12-tetramethyl-17-methylidene-9,15-dioxo-2,14-dioxatetracyclo[8.6.1.0¹,¹².0³,⁸]heptadecan-7-yl]acetate
(1s,3r,7r,10s,12s,13r,15r,17s,18r,21r,22s,23s,25s,29s)-12,18-dihydroxy-9,9,18,23,25-pentamethyl-4,8,16,20,28-pentaoxaoctacyclo[13.12.1.1¹⁵,²².0¹,¹³.0³,⁷.0³,¹⁰.0¹⁷,²¹.0²⁵,²⁹]nonacosane-5,14,19,24-tetrone
(1s,3r,7r,10s,12s,13r,15s,17r,18s,21r,22s,23r,25s,29s)-7,12-dihydroxy-9,9,18,23,25-pentamethyl-4,8,16,20,28-pentaoxaoctacyclo[13.12.1.1¹⁵,²².0¹,¹³.0³,⁷.0³,¹⁰.0¹⁷,²¹.0²⁵,²⁹]nonacosane-5,14,19,24-tetrone
[(1r,5s,10s,11s,12r,13s,14s,16s)-14-(acetyloxy)-5,11,13,16-tetrahydroxy-10-(2-hydroxypropan-2-yl)-7-methyl-4-oxo-3-oxatetracyclo[10.4.0.0¹,⁵.0⁶,¹⁰]hexadec-6-en-13-yl]methyl benzoate
3,9,22,23-tetrahydroxy-1,5,20-trimethyl-6-(5-oxo-2h-furan-3-yl)-11,17,19,24-tetraoxaheptacyclo[12.12.0.0²,¹⁰.0⁵,⁹.0¹⁰,¹².0¹⁶,²⁵.0¹⁸,²³]hexacos-14-en-4-one
(1s,2r,3s,5r,6r,9r,10r,12s,14r,16r,18s,20r,23r,25r)-3,9,23-trihydroxy-1,5,20-trimethyl-6-(5-oxo-2h-furan-3-yl)-11,17,19,24-tetraoxaheptacyclo[12.12.0.0²,¹⁰.0⁵,⁹.0¹⁰,¹².0¹⁶,²⁵.0¹⁸,²³]hexacosane-4,22-dione
(1s,3r,7r,10s,12s,13r,15s,17s,18r,21r,22s,23r,25s,29s)-12,18-dihydroxy-9,9,18,23,25-pentamethyl-4,8,16,20,28-pentaoxaoctacyclo[13.12.1.1¹⁵,²².0¹,¹³.0³,⁷.0³,¹⁰.0¹⁷,²¹.0²⁵,²⁹]nonacosane-5,14,19,24-tetrone
5-(acetyloxy)-4,7,9,12-tetrahydroxy-4-(hydroxymethyl)-8,11,14,14-tetramethyl-16-oxo-15-oxatetracyclo[7.4.3.0¹,¹⁰.0³,⁸]hexadec-10-en-2-yl benzoate
methyl (2s)-2-[(1s,2r,3s,4r,7s,8s,12r,14r,15s,16r,17s,18s)-1-(acetyloxy)-8-(furan-3-yl)-3,15-dihydroxy-7,16,18-trimethyl-10-oxo-9,13-dioxahexacyclo[14.2.1.0²,¹⁴.0³,¹².0⁴,¹⁸.0⁷,¹²]nonadecan-17-yl]-2-hydroxyacetate
1,3,6-tri(4-hydroxybenzyl)-4-methoxydihydro-phenanthrene-2,7-diol
{"Ingredient_id": "HBIN001085","Ingredient_name": "1,3,6-tri(4-hydroxybenzyl)-4-methoxydihydro-phenanthrene-2,7-diol","Alias": "NA","Ingredient_formula": "C36H32O6","Ingredient_Smile": "COC1=C(C(=C(C2=C1C3=CC(=C(C=C3CC2)O)CC4=CC=C(C=C4)O)CC5=CC=C(C=C5)O)O)CC6=CC=C(C=C6)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "21674","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
14beta-hudroxy-10-deacetylbaccatin iii
{"Ingredient_id": "HBIN001382","Ingredient_name": "14beta-hudroxy-10-deacetylbaccatin iii","Alias": "NA","Ingredient_formula": "C29H36O11","Ingredient_Smile": "CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(C(C1O)O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "31174","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
14β-hydroxy-10-deacetylbaccatin iii
{"Ingredient_id": "HBIN001383","Ingredient_name": "14\u03b2-hydroxy-10-deacetylbaccatin iii","Alias": "NA","Ingredient_formula": "C29H36O11","Ingredient_Smile": "CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(C(C1O)O)O)OC(=O)C5=CC=CC=C5)(CO4)OC(=O)C)O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9961","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-debenzoyl-14beta-benzoyloxy-10-deacetylbaccatin iii
{"Ingredient_id": "HBIN005511","Ingredient_name": "2-debenzoyl-14beta-benzoyloxy-10-deacetylbaccatin iii","Alias": "2-debenzoyl-14\u03b2-benzoyloxy-10-deacetyl-baccatin iii","Ingredient_formula": "C29H36O11","Ingredient_Smile": "CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(C(C1O)OC(=O)C5=CC=CC=C5)O)O)(CO4)OC(=O)C)O)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "26020;4802","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}